HOXA10 acts as a lifelong protector of skeletal stem cell pools by promoting self-renewal and suppressing premature maturation into osteoblasts, thereby preserving bone healing capacity and keeping collagen alignment conducive to repair.

Across the lifespan, HOXA10 serves as a brake on premature maturation and helps align collagen fibers at fracture sites, enabling effective bone repair and preserving healing potential over time.

Key researchers include Philipp Leucht, MD, PhD, and NYU Langone Health collaborators; the work was published online in Science Advances on November 4.

Researchers tagged HOXA10-expressing stem cells with a fluorescent marker and used controllable gene-off systems to track cell status across life stages in mice.

The study used genetically engineered mice with HOXA10-tagged stem cells and controllable HOXA10 expression to monitor self-renewal and maturation dynamics throughout the lifespan.

In addition to mouse data, human cell experiments showed consistent trends, tracing HOXA10-expressing cell fate with similar patterns of maintenance and maturation.

Human cells silenced for HOX genes showed reduced stem cell numbers and increased apoptosis, underscoring HOX genes’ importance for long-term skeletal stem cell maintenance in humans.

HOX genes are viewed as body 'zip codes' for cell positioning, and this study confirms their active role in maintaining adult skeletal stem cells beyond embryonic development.

The findings build on prior work showing HOXA10 can improve fracture healing in older mice and position HOX genes as potential therapeutic targets to enhance bone regeneration.

In mice lacking HOXA10, fracture healing was impaired with fewer stem cell progenitors in the healing callus and disordered collagen formation; newborn deletion caused a drastic 90 percent loss of bone stem cells over 15 months.

HOXA10-positive cells in the periosteum show superior self-renewal, marking a readily available reservoir of healing-competent cells.

Funding and affiliations: NYU Langone Health and NYU Grossman School of Medicine led by Philipp Leucht, with NIH support (R21AR081268, R01AG086058) and Musculoskeletal Transplant Foundation backing.